Landos Biopharma Inc. (LABP)

Stock Card

$22.91

$0.11 (0.50%)

As on 23-May-2024 16:37EDT

Market cap

$72 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

2.1

Div. Yield

0 %

Landos Biopharma (LABP) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: -- High: --

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-4 Mln
ROE

-0.7 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

0.3
Debt to Equity

0
Book Value

$--
EPS

$-4
Face value

--
Shares outstanding

3,125,840

6 Years Aggregate

CFO

$-133.04 Mln

EBITDA

$-150.30 Mln

Net Profit

$-148.27 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Landos Biopharma (LABP)	526.0	4.3	296.4	655.9	-42.5	--	--
BSE Sensex^*	-10.1	-2.5	2.0	-5.0	5.2	5.7	10.3
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 23-May-2024 | *As on 03-Sep-2026 | #As on 26-Oct-2023

Company	2023	2022
Landos Biopharma (LABP)	-26.8	-89.6
S&P Small-Cap 600	13.9	-17.4
BSE Sensex	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Landos Biopharma (LABP)	22.9	71.7	0.0	-24.8	--	-81.5	--	2.1
Atreca Inc. Class A (BCEL)	0.1	3.6	0.3	-95.1	-21,828.5	-265.1	--	0.3
Deciphera Pharmaceuticals LLC (DCPH)	25.6	2,212.9	174.9	-190.4	-118.4	-54.6	--	7.0
First Wave BioPharma (FWBI)	2.1	6.0	0.1	-6.2	-15,087.2	-15.2	--	1.9

Shareholding Pattern

View Details

About Landos Biopharma (LABP)

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1),... a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia. As of May 23, 2024, Landos Biopharma, Inc. operates as a subsidiary of AbbVie Inc. Read more

President, CEO & Director

Mr. Gregory Oakes
President, CEO & Director

Mr. Gregory Oakes
Headquarters

Blacksburg, VA
Website

https://landosbiopharma.com

FAQs for Landos Biopharma (LABP)

What is the current share price of Landos Biopharma Inc (LABP) Today?

The share price of Landos Biopharma Inc (LABP) is $22.91 (NASDAQ) as of 23-May-2024 16:37 EDT. Landos Biopharma Inc (LABP) has given a return of -42.51% in the last 3 years.

What is the current PB & PE ratio of Landos Biopharma Inc (LABP)?

Since, TTM earnings of Landos Biopharma Inc (LABP) is negative, P/E ratio is not available.
The P/B ratio of Landos Biopharma Inc (LABP) is 2.11 times as on 11-Jun-2024, a 59 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2023	-1.04	0.71
2022	-0.05	0.05
2021	-0.51	0.25
2020	--	--
2019	--	--

What is the 52 Week High and Low of Landos Biopharma Inc (LABP)?

The 52-week high and low of Landos Biopharma Inc (LABP) are Rs -- and Rs -- as of 03-Sep-2026.

What is the market cap of Landos Biopharma Inc (LABP)?

Landos Biopharma Inc (LABP) has a market capitalisation of $ 72 Mln as on 11-Jun-2024. As per SEBI classification, it is a Small Cap company.

Should I invest in Landos Biopharma Inc (LABP)?

Before investing in Landos Biopharma Inc (LABP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.